194804-92-7

Basic information

• Product Name: 4-BROMO-2-FLUORO-3-METHOXY-BENZOIC ACID
• Synonyms: 4-BROMO-2-FLUORO-3-METHOXY-BENZOIC ACID
• CAS NO: 194804-92-7
• Molecular Formula: C₈H₆BrFO₃
• Molecular Weight: 249.03
• Mol File: 194804-92-7.mol

Chemical Properties

• Melting Point: 168-170 °C
• Boiling Point: 331 °C at 760 mmHg
• Flash Point: 154 °C
• Appearance: /
• Density: 1.701 g/cm³
• Vapor Pressure: 6.41E-05mmHg at 25°C
• Refractive Index: 1.563
• PKA: 2.92±0.10(Predicted)
• Sensitive: Light Sensitive/Air Sensitive
• CAS DataBase Reference: 4-BROMO-2-FLUORO-3-METHOXY-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2-FLUORO-3-METHOXY-BENZOIC ACID(194804-92-7)
• EPA Substance Registry System: 4-BROMO-2-FLUORO-3-METHOXY-BENZOIC ACID(194804-92-7)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• Hazardous Substances Data: 194804-92-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMO-2-FLUORO-3-METHOXY-BENZOIC ACID is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of diverse molecular structures, making it a valuable building block in the development of new drugs with improved therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical industry, 4-BROMO-2-FLUORO-3-METHOXY-BENZOIC ACID serves as a crucial component in the synthesis of various agrochemicals, such as pesticides and herbicides. Its halogenated nature and functional groups contribute to the development of effective and targeted agrochemicals for crop protection and management.
Used in Organic Synthesis:
4-BROMO-2-FLUORO-3-METHOXY-BENZOIC ACID is utilized as a versatile building block in organic synthesis for the creation of a wide range of chemical compounds. Its presence of fluorine, bromine, and methoxy groups enables the formation of various molecular structures, making it a valuable precursor in the synthesis of specialty chemicals, materials, and other organic compounds.

InChI:InChI=1/C8H6BrFO3/c1-13-7-5(9)3-2-4(6(7)10)8(11)12/h2-3H,1H3,(H,11,12)

Upstream product

• 845829-94-9 1-bromo-3-fluoro-2-methoxybenzene 
• 124-38-9 carbon dioxide 
• 1526-17-6 2-fluoro-6-nitrophenol 
• 437-83-2 3-fluoro-2-methoxyaniline 
• 484-94-6 1-fluoro-2-methoxy-3-nitrobenzene 
• 367-12-4 2-fluorophenol 

Downstream Products

• 194804-99-4 ethyl 3-(4-bromo-2-fluoro-3-methoxyphenyl)-3-oxopropionate 
• 1426073-33-7 4-bromo-2-fluoro-3-methoxybenzonitrile 

Relevant articles and documents

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula(I) or a pharmaceutically acceptable salt thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure, kidney disease, edema, and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: Effects of structural modifications at the 6-, 7-, and 8-positions

We describe the biological evaluation of isothiazoloquinolones (ITQs) having structural modifications at the 6-, 7-, and 8-positions. Addition of a methoxy substituent to C-8 effected an increase in antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and a decrease in cytotoxic activity against Hep2 cells. Removal of fluorine from C-6 or replacement of the C-8 carbon with a nitrogen compromised anti-MRSA activity. When the groups attached at C-7 were compared, the anti-MRSA activity decreased in the order 6-isoquinolinyl > 4-pyridinyl > 5-dihydroisoindolyl > 6-tetrahydroisoquinolinyl. The compound with the most desirable in vitro biological profile was 9-cyclopropyl-6-fluoro-8-methoxy-7-(2-methylpyridin-4-yl) -9H-isothiazolo[5,4-b]quinoline-3,4-dione (7g). This ITQ demonstrated (i) strong in vitro anti-MRSA activity (MIC90 = 0.5 μg/mL), (ii) strong inhibitory activities against S. aureus DNA gyrase and topoisomerase IV, with weak activity against human topoisomerase II, (iii) weak cytotoxic activities against three cell lines, and (iv) efficacy in an in vivo murine thigh model of infection employing MRSA.

NEW ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS

The invention provides certain compounds and salts of Formula I and Formula II:which possess antimicrobial activity. The invention also provides novel synthetic intermediatesuseful in making compounds of Formula I and Formula II. The variables A1, R2, R3, R5, R6, R7, A8, and Rg are defined herein. Certain compounds of Formula I and Formula II disclosed herein are potent and selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula I or Formula II as the only active agent or may contain a combination of a compound of Formula I or Formula II and one or more other active agents. The invention also provides methods for treating microbial infections in animals.